You’ve been prescribed MENOPUR^®, the only gonadotropin approved by the FDA on the basis of pregnancy rates. MENOPUR^® is the most widely used and extensively studied reproductive hormone, proven to be both safe and effective.

As part of an Assisted Reproductive Technology (ART) program, MENOPUR^® is administered by subcutaneous (SC) injection only and is used to induce the development of multiple eggs and pregnancy in women who are able to produce and release eggs (ovulate). Its unique purity is also associated with less discomfort at the injection site, an important point for many women.

MENOPUR^® is a highly purified preparation of naturally derived gonadotropins, called hMG. MENOPUR^® contains equal amounts (75 IUs) of 2 kinds of hormonal activity: follicle-stimulating hormone (FSH), which helps stimulate egg production; and luteinizing hormone (LH), which helps the eggs mature and release (ovulate). MENOPUR^® helps stimulate eggs to mature in women whose ovaries are basically healthy but are unable to develop eggs. It is not used for women who suffer from ovarian failure.

MENOPUR^® is usually used together with human chorionic gonadotropin (hCG), and is indicated for the development of multiple follicles and pregnancy in women participating in an Assisted Reproductive Technology (ART) program.

In an IVF trial of over 700 women, the efficacy and safety of MENOPUR^® was compared to a previously available treatment, recombinant FSH. While prior treatments had been approved on the basis of number of oocytes (eggs), due to the results of this study, MENOPUR^® became the first and only gonadotropin treatment approved by the FDA on the basis of pregnancy rates, the true measure of clinical effectiveness.²

Other clinical studies have shown that treatment with MENOPUR^® was shown to have a significant impact on the quality of the developing embryo, and to significantly impact pregnancy and birth rates.^3-5

MENOPUR^® is available by prescription in 5 mL vials containing 75 IU FSH and 75 IU LH activity with accompanying diluent.

MENOPUR^® administered subcutaneously is indicated for the development of multiple follicles and pregnancy in the ovulatory patients participating in an ART program.

Important Safety Information

Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe MENOPUR^®. MENOPUR^®, like all gonadotropins, is a potent substance capable of causing mild to severe adverse reactions, including OHSS (overall incidence 3.8%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. MENOPUR^® is contraindicated in women who have a high FSH level indicating primary ovarian failure; uncontrolled thyroid and adrenal dysfunction; an organic intracranial lesion such as a pituitary tumor; sex hormone dependent tumors of the reproductive tract and accessory organs; abnormal uterine bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome; prior hypersensitivity to menotropins or MENOPUR^®. MENOPUR^® is not indicated in women who are pregnant. There are limited human data on the effects of menotropins when administered during pregnancy.

Click here to see Full Prescribing Information for MENOPUR^®.

References: 1. Keye WR, Webster B, Dickey R, et al. Subcutaneously administered MENOPUR, a new highly purified human menopausal gonadotropin causes significantly fewer injection site reactions than REPRONEX^® in subjects undergoing in vitro fertilization. Reprod Biol Endocrinol. In press. 2. The European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone. Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial. Fertil Steril. 2002;78:520-528. 3. Ziebe S, Lundin K, Janssens R, et al. Influence of ovarian stimulation with HP-hMG or recombinant FSH on embryo quality parameters in patients undergoing IVF. Hum Reprod. 2007;22:2404-2413. 4. Weghofer A, Munné S, Brannath W, et al. The impact of LH-containing gonadotropins on diploidy rates in preimplantation embryos: long protocol stimulation. Hum Reprod. 2008;23:499-503. 5. Platteau P, Andersen AN, Loft A, et al. Highly purified hMG versus recombinant FSH for ovarian stimulation in IVF cycles. Reprod Biomed Online. 2008;17:190-198.

Previous: BRAVELLE® FAQs

Next: Injecting MENOPUR®